New search Hide text from Guidelines
C CARDIOVASCULAR SYSTEMThis group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.
C10 LIPID MODIFYING AGENTS
| The DDDs are based on the treatment of hypercholesterolemia. |
C10B LIPID MODIFYING AGENTS, COMBINATIONS
Fixed combinations of blood glucose-lowering drugs and lipid modifying agents are classified in A10B.
| For fixed combinations in C10B the DDD is based on dosing frequency only. This implies that 1 UD (1 tablet) is the DDD for all products given once daily and the DDD for products given twice daily and three times daily is 2 UD (2 tablets) and 3 UD (3 tablets) respectively. |
C10BA Combinations of various lipid modifying agents
| ATC code | Name | DDD | U | Adm.R | Note |
| C10BA01 | lovastatin and nicotinic acid | ||||
| C10BA02 | simvastatin and ezetimibe | ||||
| C10BA03 | pravastatin and fenofibrate | ||||
| C10BA04 | simvastatin and fenofibrate | ||||
| C10BA05 | atorvastatin and ezetimibe | ||||
| C10BA06 | rosuvastatin and ezetimibe | ||||
| C10BA07 | rosuvastatin and omega-3 fatty acids | ||||
| C10BA08 | atorvastatin and omega-3 fatty acids | ||||
| C10BA09 | rosuvastatin and fenofibrate | ||||
| C10BA10 | bempedoic acid and ezetimibe | ||||
| C10BA11 | pravastatin and ezetimibe | ||||
| C10BA12 | pravastatin, ezetimibe and fenofibrate |
Last updated: 2024-01-26